利用高通量人体气道微生理系统预测SARS-CoV-2药物疗效的临床结果（生物学进展 11/2024）

IF 3.2 3区生物学 Q3 MATERIALS SCIENCE, BIOMATERIALS

Advanced biology Pub Date : 2024-11-12 DOI:10.1002/adbi.202470111

Landys Lopez Quezada, Felix Mba Medie, Rebeccah J. Luu, Robert B. Gaibler, Elizabeth P. Gabriel, Logan D. Rubio, Thomas J. Mulhern, Elizabeth E. Marr, Jeffrey T. Borenstein, Christine R. Fisher, Ashley L. Gard

{"title":"利用高通量人体气道微生理系统预测SARS-CoV-2药物疗效的临床结果（生物学进展 11/2024）","authors":"Landys Lopez Quezada, Felix Mba Medie, Rebeccah J. Luu, Robert B. Gaibler, Elizabeth P. Gabriel, Logan D. Rubio, Thomas J. Mulhern, Elizabeth E. Marr, Jeffrey T. Borenstein, Christine R. Fisher, Ashley L. Gard","doi":"10.1002/adbi.202470111","DOIUrl":null,"url":null,"abstract":"<p><b>SARS-CoV-2 Drug Efficacy</b></p><p>Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":7234,"journal":{"name":"Advanced biology","volume":"8 11","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adbi.202470111","citationCount":"0","resultStr":"{\"title\":\"Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System (Adv. Biology 11/2024)\",\"authors\":\"Landys Lopez Quezada, Felix Mba Medie, Rebeccah J. Luu, Robert B. Gaibler, Elizabeth P. Gabriel, Logan D. Rubio, Thomas J. Mulhern, Elizabeth E. Marr, Jeffrey T. Borenstein, Christine R. Fisher, Ashley L. Gard\",\"doi\":\"10.1002/adbi.202470111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>SARS-CoV-2 Drug Efficacy</b></p><p>Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":7234,\"journal\":{\"name\":\"Advanced biology\",\"volume\":\"8 11\",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adbi.202470111\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adbi.202470111\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biology","FirstCategoryId":"99","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adbi.202470111","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

摘要

SARS-CoV-2 药物疗效快速确定治疗新发传染病的有效疗法需要能在高封闭性实验室环境中进行大规模操作的预测性临床前药物筛选工具。在文章编号 2300511 中，Ashley L. Gard、Christine R. Fisher 和 Draper 的合作者使用高通量人体气道微生理系统 PREDICT96-ALI 评估了几种 SARS-CoV-2 干预措施的疗效，并区分了无效的先导化合物和临床有效的抗病毒药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System (Adv. Biology 11/2024)

查看原文本刊更多论文

Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System (Adv. Biology 11/2024)

SARS-CoV-2 Drug Efficacy

Rapid identification of effective therapeutics for emerging infectious diseases requires predictive preclinical drug screening tools that are operable at scale in high-containment laboratory environments. In article number 2300511 Ashley L. Gard, Christine R. Fisher, and co-workers at Draper used a high-throughput human airway microphysiological system, PREDICT96-ALI, to evaluate the efficacy of several SARS-CoV-2 interventions and distinguish ineffective lead compounds from clinically efficacious antivirals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advanced biology Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

6.60

自引率

0.00%

发文量

130